Purpose: Epithelial-to-mesenchymal transition (EMT) confers resistance to a number of
targeted therapies and chemotherapies. However, it has been unclear why EMT promotes�…

While significant advancements have been made in the available therapies for metastatic
non-small cell lung cancer (NSCLC), acquired resistance remains a major barrier to�…

Cysteine-focused chemical proteomic platforms have accelerated the clinical development
of covalent inhibitors for a wide range of targets in cancer. However, how different oncogenic�…

Several cancer immunotherapy approaches, such as immune checkpoint blockade and
adoptive T-cell therapy, boost T-cell activity against the tumor, but these strategies are not�…

Novel coronavirus disease 2019 (COVID-19) severity is highly variable, with pediatric
patients typically experiencing less severe infection than adults and especially the elderly�…

Histologic transformation from non-small cell to small cell lung cancer has been reported as
a resistance mechanism to targeted therapy in EGFR-mutant and ALK fusion-positive lung�…

Targeted therapies have changed the landscape of treatments for non-small cell lung cancer
(NSCLC). Specific targeted therapies have been approved for NSCLC patients harboring�…

ROS1 tyrosine kinase inhibitors (TKI) have been approved (crizotinib and entrectinib) or
explored (lorlatinib, taletrectinib, and repotrectinib) for the treatment of ROS1 fusion–positive�…

Resistance looms for KRASG12C inhibitors | Nature Medicine Skip to main content Thank you
for visiting nature.com. You are using a browser version with limited support for CSS. To�…

Signal transducer and activator of transcription 3 (STAT3) has a critical role in regulating cell
fate, inflammation and immunity,. Cytokines and growth factors activate STAT3 through�…